Rolf Lamerz

TL;DR: Recommendations to encourage optimal use of tumor markers for 5 cancer sites were critically reviewed and alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring.

TL;DR: New guidelines for the use of serum, tissue and faecal markers in colorectal cancer (CRC) are presented and insufficient evidence exists to recommend routine use of tissue factors such as thymidylate synthase, microsatellite instability, p53, K-ras and deleted in colon cancer (DCC).

TL;DR: The aim of this article was to provide guidelines for the routine clinical use of some of these markers, including carcinoembryonic antigen (CEA), for colorectal cancer detection and monitoring purposes.

TL;DR: Recommendations are presented for the routine clinical use of serum and tissue-based markers in the diagnosis and management of patients with breast cancer and recently validated prognostic markers for lymph node-negative breast cancer patients may be of value in selecting node- negative patients that do not require adjuvant chemotherapy.

TL;DR: In patients with resectable pancreatic cancer, presurgical and postresection CA 19-9 levels correlate with overall survival and thus may be combined with other factors for risk stratification, and most, but not all, reports indicate that serial levels of CA19-9 correlate with response to systemic therapy.